Last reviewed · How we verify
MTBVAC live vaccine
At a glance
| Generic name | MTBVAC live vaccine |
|---|---|
| Sponsor | Biofabri, S.L |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Safety and Immunogenicity of MTBVAC (PHASE2)
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) (PHASE2)
- Tuberculosis Vaccine in Healthy Indian Adults (PHASE1)
- Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates (PHASE2)
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (PHASE3)
- Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults (PHASE1, PHASE2)
- Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MTBVAC live vaccine CI brief — competitive landscape report
- MTBVAC live vaccine updates RSS · CI watch RSS
- Biofabri, S.L portfolio CI